Xeris Biopharma Holdings, Inc.
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $291.8M
- Net income
- $554.0K
- Total assets
- $383.5M
- Market cap
- $1.1B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Balance sheet
- Total assets
- $392.0M
- Current assets
- $251.7M
- Total liabilities
- $379.0M
- Current liabilities
- $118.6M
- Shareholders’ equity
- $13.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.1B
- Shares outstanding
- 171.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 21, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $554.0K in FY2025.
- Revenue grew 165% from FY2022 to FY2025.
- Trading 37% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Xeris Biopharma Holdings, Inc..
Write a review
News about Xeris Biopharma Holdings, Inc.
News & sentiment via Polygon.io
